Abstract： Objective:To explore the clinical efficacy and safety of albumin-binding paclitaxel combined with intraperitoneal perfusion therapy in the treatment of advanced ovarian cancer.Methods:A total of 80 patients with advanced ovarian cancer admitted to our hospital from January 2019 to January 2022 were randomly divided into control group and observation group,with 40 cases in each group.The control group was treated with albumin-binding paclitaxel and cisplatin,the observation group was treated with albumin-binding paclitaxel combined with cisplatin intraperitoneal hyperthermic perfusion chemotherapy(IHPC).The clinical efficacy,tumor marker levels,immune function indicators and adverse reactions were compared between the two groups.Results:The effective rate of recent treatment in the observation group was 92.50%,which was higher than 75.00%in the control group(P<0.05).After treatment,the levels of CEA,CA125,CA199 and HE4 in the observation group were lower than those in the control group,and the levels of CD3+,CD4+,CD8+ and NK were higher than those in the control group(P<0.05).There was no significant difference in the incidence of gastrointestinal reaction,bone marrow suppression,joint pain and renal dysfunction between the two groups(P>0.05).Conclusion:The short-term efficacy of albumin-binding paclitaxel combined with intraperitoneal perfusion therapy in patients with advanced ovarian cancer is good,which can regulate the level of tumor markers and immune function,and the safety factor is high.